Press Release

(October 4, 2021) - EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials

SAN DIEGO, October 4, 2021 — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today that it expects to supply its proprietary CleanCap® ...

(August 3, 2021) - TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries.

SAN DIEGO — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics ap...

(March 15, 2021) - New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing.

SAN DIEGO — Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTec...

(August 25, 2020) - Second manufacturing expansion within a year will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical grade APIs to include mRNA, self-amplifying RNA and plasmid DNA

SAN DIEGO, Calif. — Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriL...

(April 27, 2020) - SAN DIEGO –TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at ...

(February 11, 2020) - SAN DIEGO – TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today the addition of two key executives to its leadership team.

Ray Kaczmarek joins TriLink as senior vice president of GMP operations. Kaczmarek, who has over 20 years of experience in pharmaceutical and biotechnology manufacturing and supply chain operations, most recently served as president of Nitto Avecia Pharma Services, a contract development and manufacturing organization support...

(January 7, 2020) - Advancements Expected to Accelerate Development of mRNA Therapeutics

SAN DIEGO  – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. Both patents cover advancements in TriLink’s CleanCap® technology for the co-transcriptional capping of messenger RNAs (mRNAs). Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid therapeutics tha...

In the News

At Least 6 Companies Working on COVID Vaccines in San Diego

(10 News San Diego: June 24, 2020) - At least six companies are working on COVID-19 vaccine candidates in San Diego, all within a 1.5-mile radius of where the I-5 and I-805 split. Locally, the farthest along appears to be Inovio Pharmaceuticals, which plans to launch a Phase 2 trial next month, potentially with a simultaneous Phase 3 trial. A Phase 3 trial is the final step in vaccine testing, with thousands of participants. The company is develop...

Coronavirus: Human Trial of New Vaccine Begins in UK

(BBC News: June 24, 2020) - Volunteers have begun being immunised with a new UK coronavirus vaccine. About 300 people will have the vaccine over the coming weeks, as part of a trial led by Prof Robin Shattock and his colleagues, at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response. Experts at Oxford University have already started human trials. The trials are among many across the...

mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth

(Genetic Engineering & Biotechnology News: December 20, 2019) - A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city...

Sara Michelmore
MacDougall
Phone: +1 781-235-3060
Email: [email protected]

""